Abstract
Drug-induced nephrolithiasis can arise from insoluble components within medications
or crystallization of metabolites due to changes in metabolism and urinary pH. The
connection between drugs utilized for iron chelation therapy (ICT) and nephrolithiasis
is not well understood. In this report, we describe two pediatric patients diagnosed
with nephrolithiasis while undergoing treatment with the chelating agents deferasirox,
deferiprone, and deferoxamine for iron overload secondary to repeat blood transfusion
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Drug-induced kidney stones and crystalline nephropathy: Pathophysiology, prevention and treatment.Drugs. 2018; 78: 163-201https://doi.org/10.1007/s40265-017-0853-7
- Physiology and pathophysiology of iron in hemoglobin-associated diseases.Free Radic Biol Med. 2014; 72: 23-40https://doi.org/10.1016/j.freeradbiomed.2014.03.039
- Drug-induced urolithiasis in pediatric patients.Paediatr Drugs. 2019; 21: 323-344https://doi.org/10.1007/s40272-019-00355-5
- High incidence of renal stones in severely disabled children with epilepsy treated with topiramate.Neuropediatrics. 2019; 50: 160-163https://doi.org/10.1055/s-0038-1676287
- Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria.Bone. 2016; 85 (https://doi.org/0.1016/j.bone.2016.01.011): 55-58
- Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.BMC Nephrol. 2021; 22 (https://doi): 418https://doi.org/10.1186/s12882-021-02630-5
- Nephrolithiasis in transfusion-dependent pediatric patients.Blood. 2014; 124: 4895https://doi.org/10.1182/blood.V124.21.4895.4895
- Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.Ann Hematol. 2013; 92: 263-265https://doi.org/10.1007/s00277-012-1558-3
- Thalassemia bone disease: The association between nephrolithiasis, bone mineral density and fractures.Osteoporos. Int. 2013; 24 (https://doi.org/s00198-012-2260-y): 1965-1971
- Kidney stones in transfusion-dependent thalassemia: Prevalence and risk factors.Open Journal of Urology. 2022; 12: 209-227https://doi.org/10.4236/oju.2022.124021
Article info
Publication history
Accepted:
March 10,
2023
Received in revised form:
February 10,
2023
Received:
October 3,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Published by Elsevier Ltd.
